CD19 scFv-CD28-OX40-CD3ζ (3rd) CAR Expression Plasmid

INTRODUCTION

Chimeric Antigen Receptors (CARs) are recombinant receptors that are composed of four regions: an antigen recognition domain (ectodomain), a hinge region, a transmembrane region, and an intracellular T cell signaling domain (endodomain). CAR-T cell therapy uses T cells engineered with CARs to target specific antigen(s) for cancer immunotherapy.

CD19 is a member of the immunoglobulin gene superfamily. It is a cell surface protein and its expression is restricted to B cell lymphocytes. CD19 is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. CD19 protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia.

RGBiotech offers CD19 scFv-CD28-OX40-CD3ζ (3rd) CAR Expression Plasmid to assist CAR-T research. This vector contains a third (3rd) generation of CD19 CAR that consists of four major components: 1) anti-CD19 scFv as an extracellular CD19-binding domain, 2) a hinge region, 3) a transmembrane domain, and 4) CD28, OX40 (TNFRSF4, CD134) and CD3ζ (CDzeta, CD247) intracellular signaling domains.

HIGHLIGHTS

APPLICATIONS

Contact Us